Fidelity Investments’s Travere Therapeutics TVTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $326M | Buy |
10,967,967
+1,350,104
| +14% | +$40.4M | 0.02% | 662 |
|
|
2025
Q4 | $367M | Buy |
9,617,863
+6,723,715
| +232% | +$219M | 0.02% | 617 |
|
|
2025
Q3 | $69.2M | Buy |
2,894,148
+1,826,375
| +171% | +$34.3M | ﹤0.01% | 1324 |
|
|
2025
Q2 | $15.8M | Sell |
1,067,773
-13,929
| -1% | -$231K | ﹤0.01% | 1765 |
|
|
2025
Q1 | $19.4M | Sell |
1,081,702
-38,314
| -3% | -$778K | ﹤0.01% | 1691 |
|
|
2024
Q4 | $19.5M | Buy |
1,120,016
+972,600
| +660% | +$17.2M | ﹤0.01% | 1736 |
|
|
2024
Q3 | $2.06M | Buy |
147,416
+31,772
| +27% | +$331K | ﹤0.01% | 2395 |
|
|
2024
Q2 | $951K | Buy |
115,644
+39,816
| +53% | +$268K | ﹤0.01% | 2538 |
|
|
2024
Q1 | $585K | Sell |
75,828
-1,036
| -1% | -$8.74K | ﹤0.01% | 2672 |
|
|
2023
Q4 | $691K | Sell |
76,864
-8,995
| -10% | -$65.5K | ﹤0.01% | 2582 |
|
|
2023
Q3 | $768K | Buy |
85,859
+24,175
| +39% | +$341K | ﹤0.01% | 2522 |
|
|
2023
Q2 | $947K | Sell |
61,684
-154,076
| -71% | -$2.8M | ﹤0.01% | 2487 |
|
|
2023
Q1 | $4.85M | Buy |
215,760
+35,593
| +20% | +$757K | ﹤0.01% | 2098 |
|
|
2022
Q4 | $3.79M | Sell |
180,167
-238,738
| -57% | -$5.06M | ﹤0.01% | 2196 |
|
|
2022
Q3 | $10.3M | Sell |
418,905
-19,909
| -5% | -$514K | ﹤0.01% | 1883 |
|
|
2022
Q2 | $10.6M | Buy |
438,814
+20,630
| +5% | +$519K | ﹤0.01% | 1946 |
|
|
2022
Q1 | $10.8M | Buy |
418,184
+45,256
| +12% | +$1.2M | ﹤0.01% | 2092 |
|
|
2021
Q4 | $11.6M | Hold |
372,928
| – | – | ﹤0.01% | 2057 |
|
|
2021
Q3 | $9.04M | Buy |
372,928
+360,629
| +2,932% | +$6.63M | ﹤0.01% | 2170 |
|
|
2021
Q2 | $179K | Sell |
12,299
-587,300
| -98% | -$11.6M | ﹤0.01% | 2938 |
|
|
2021
Q1 | $15M | Sell |
599,599
-67,900
| -10% | -$1.88M | ﹤0.01% | 1894 |
|
|
2020
Q4 | $18.2M | Sell |
667,499
-146,200
| -18% | -$3.41M | ﹤0.01% | 1753 |
|
|
2020
Q3 | $15M | Hold |
813,699
| – | – | ﹤0.01% | 1687 |
|
|
2020
Q2 | $16.6M | Sell |
813,699
-43,000
| -5% | -$685K | ﹤0.01% | 1624 |
|
|
2020
Q1 | $12.5M | Buy |
856,699
+432,500
| +102% | +$6.51M | ﹤0.01% | 1622 |
|
|
2019
Q4 | $6.02M | Sell |
424,199
-212,736
| -33% | -$2.72M | ﹤0.01% | 2004 |
|
|
2019
Q3 | $7.38M | Sell |
636,935
-516,864
| -45% | -$8.54M | ﹤0.01% | 1931 |
|
|
2019
Q2 | $23.2M | Buy |
1,153,799
+258,754
| +29% | +$5.11M | ﹤0.01% | 1559 |
|
|
2019
Q1 | $20.3M | Buy |
895,045
+311,100
| +53% | +$6.87M | ﹤0.01% | 1605 |
|
|
2018
Q4 | $13.2M | Sell |
583,945
-247,983
| -30% | -$6.17M | ﹤0.01% | 1710 |
|
|
2018
Q3 | $23.9M | Sell |
831,928
-257,800
| -24% | -$7.37M | ﹤0.01% | 1604 |
|
|
2018
Q2 | $29.7M | Hold |
1,089,728
| – | – | ﹤0.01% | 1525 |
|
|
2018
Q1 | $24.4M | Sell |
1,089,728
-249,917
| -19% | -$5.95M | ﹤0.01% | 1639 |
|
|
2017
Q4 | $28.2M | Sell |
1,339,645
-489,430
| -27% | -$11.2M | ﹤0.01% | 1558 |
|
|
2017
Q3 | $45.5M | Sell |
1,829,075
-70,700
| -4% | -$1.56M | 0.01% | 1343 |
|
|
2017
Q2 | $36.8M | Sell |
1,899,775
-59,100
| -3% | -$1.07M | ﹤0.01% | 1427 |
|
|
2017
Q1 | $36.2M | Buy |
1,958,875
+389,714
| +25% | +$7.62M | ﹤0.01% | 1462 |
|
|
2016
Q4 | $29.7M | Sell |
1,569,161
-204,300
| -12% | -$4.18M | ﹤0.01% | 1526 |
|
|
2016
Q3 | $39.7M | Sell |
1,773,461
-224,009
| -11% | -$4.26M | 0.01% | 1397 |
|
|
2016
Q2 | $35.6M | Buy |
1,997,470
+767,152
| +62% | +$12.4M | ﹤0.01% | 1424 |
|
|
2016
Q1 | $16.8M | Sell |
1,230,318
-25,100
| -2% | -$381K | ﹤0.01% | 1751 |
|
|
2015
Q4 | $24.2M | Buy |
1,255,418
+647,518
| +107% | +$12.9M | ﹤0.01% | 1598 |
|
|
2015
Q3 | $12.3M | Sell |
607,900
-90,650
| -13% | -$2.69M | ﹤0.01% | 1862 |
|
|
2015
Q2 | $23.2M | Buy |
698,550
+150
| +0% | +$4.11K | ﹤0.01% | 1670 |
|
|
2015
Q1 | $16.7M | Buy |
+698,400
| New | +$10.6M | ﹤0.01% | 1795 |
|
Other funds holding TVTX
AC
PA
VCM
NAMI
SIMG
Fidelity Investments's TVTX Position: Q1 2026 in Review
Fidelity Investments increased its Travere Therapeutics (TVTX) stake by 14% in Q1 2026, buying an estimated $40.4M and bringing the position to 10,967,967 shares worth $326M. The position accounts for 0.02% of the portfolio, ranked #662.
Fidelity Investments first reported a position in TVTX in Q1 2015 and has held it in 45 quarters since. The position peaked at $367M in Q4 2025. 260 funds tracked by Wall St. Rank hold TVTX as of Q1 2026.
- Fidelity Investments held 10,967,967 shares of Travere Therapeutics worth $326M as of Q1 2026.
- Fidelity Investments bought 1,350,104 Travere Therapeutics shares in Q1 2026, an estimated $40.4M.
- Travere Therapeutics made up 0.02% of Fidelity Investments's portfolio in Q1 2026, its #662 holding.
- Fidelity Investments first reported a position in Travere Therapeutics in Q1 2015 and has held it in 45 quarters since.
- Fidelity Investments's Travere Therapeutics position peaked at $367M in Q4 2025.
- 260 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2026.
Based on Fidelity Investments's 13F filing for Q1 2026, filed 15 May 2026.